DAX23.465 +1,0%Est505.574 +0,8%MSCI World4.343 -0,1%Top 10 Crypto12,19 -2,1%Nas23.047 +0,8%Bitcoin75.343 -1,6%Euro1,1563 +0,3%Öl62,63 -1,2%Gold4.132 -0,1%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 NVIDIA 918422 DroneShield A2DMAA Bayer BAY001 Alphabet A (ex Google) A14Y6F RENK RENK73 Novo Nordisk A3EU6F Lufthansa 823212 Siemens Energy ENER6Y Amazon 906866 Deutsche Telekom 555750 Tesla A1CX3T HENSOLDT HAG000 TKMS thyssenkrupp Marine Systems TKMS00 BASF BASF11
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Dow deutlich stärker -- DAX letztlich fester -- Voting über CureVac-BioNTech-Fusion -- Zoom, D-Wave, Kohl's, Apple, Rheinmetall & Co., DroneShield, Tesla, Alibaba, Gold, AMD, TKMS im Fokus
Top News
Bitcoin-Wale schlagen wieder zu - große Investoren akkumulieren massiv Bitcoin-Wale schlagen wieder zu - große Investoren akkumulieren massiv
GAIN AI Act vor dem Aus - was das für die NVIDIA-Aktie und den US-Chipmarkt bedeutet GAIN AI Act vor dem Aus - was das für die NVIDIA-Aktie und den US-Chipmarkt bedeutet
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Halozyme Therapeutics Aktie

Kaufen
Verkaufen
Aktien-Sparplan anlegen
62,54 EUR +2,38 EUR +3,96 %
STU
72,52 USD -1,49 USD -2,01 %
BTT
Halozyme Therapeutics jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 11/2024)
Smartphone

Marktkap.7,18 Mrd. EUR

KGV13,93Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA0DLHS

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS40637H1095

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolHALO

Halozyme Therapeutics Aktien News

DatumMeistgelesen
PR NewswireHalozyme to Report Third Quarter 2024 Financial and Operating Results
PR NewswireHalozyme Announces Expansion of Global Collaboration and License Agreement with argenx for ENHANZE®
PR NewswireHalozyme Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO™ with ENHANZE® for People with Relapsing and Primary Progressive Multiple Sclerosis
PR NewswireHalozyme Announces FDA Approval of Roche's Tecentriq Hybreza™ With ENHANZE® for Multiple Types of Cancer
PR NewswireHalozyme to Present at Upcoming Investor Conferences
PR NewswireHALOZYME REPORTS SECOND QUARTER 2024 FINANCIAL AND OPERATING RESULTS
PR NewswireHalozyme to Report Second Quarter 2024 Financial and Operating Results
PR NewswireHalozyme Announces Roche's OCREVUS® SC with ENHANZE® Receives European Commission Approval for Relapsing and Primary Progressive Multiple Sclerosis
PR NewswireHalozyme Announces argenx Receives FDA Approval for VYVGART® Hytrulo Co-Formulated with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy
PR NewswireHalozyme Raises Full Year 2024 Financial Guidance and Updates 5-Year Financial Outlook
PR NewswireHalozyme Announces Issuance of New European Patent for ENHANZE® Drug Delivery Platform
PR NewswireHalozyme to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
PR NewswireHalozyme Announces Bristol Myers Squibb Received Updated Action Date from the U.S. Food and Drug Administration for Subcutaneous Nivolumab Co-Formulated with ENHANZE®
PR NewswireHalozyme to Participate in Upcoming Investor Conferences
PR NewswireHALOZYME REPORTS FIRST QUARTER 2024 FINANCIAL AND OPERATING RESULTS
PR NewswireMahesh Krishnan Elected to Halozyme's Board of Directors
PR NewswireHalozyme to Report First Quarter 2024 Financial and Operating Results
PR NewswireHalozyme to Participate in Upcoming Investor Conferences
PR NewswireHALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL AND OPERATING RESULTS
PR NewswireHalozyme To Report Fourth Quarter and Full Year 2023 Financial and Operating Results
PR NewswireHalozyme Announces Takeda Received European Commission Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
PR NewswireHalozyme Announces argenx Received Approval in Japan for VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Co-Formulated with ENHANZE® for Generalized Myasthenia Gravis
PR NewswireHalozyme Announces Takeda Receives FDA Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
PR NewswireHalozyme Announces Roche Receives European Commission Approval of Tecentriq® SC with ENHANZE® Representing the EU's First Subcutaneous PD-(L)1 Cancer Immunotherapy for Multiple Cancer Types
PR NewswireHalozyme to Host Investor Business Forum and Long-Term Outlook Call
PR NewswireHalozyme to Present at Upcoming Investor Conferences
PR NewswireHalozyme Announces argenx Receives European Commission Approval of VYVGART® SC with ENHANZE® for Generalized Myasthenia Gravis
PR NewswireHALOZYME REPORTS THIRD QUARTER 2023 FINANCIAL AND OPERATING RESULTS
PR NewswireHalozyme and Acumen Pharmaceuticals Enter Global Collaboration and Non-Exclusive License Agreement for the ENHANZE® Technology in Alzheimer's Disease
PR NewswireHalozyme To Report Third Quarter 2023 Financial and Operating Results
PR NewswirePositive Topline Results Reported from Bristol Myers Squibb's Phase 3 CheckMate-67T Trial of Subcutaneous Nivolumab with Halozyme's ENHANZE® Drug Delivery Technology for Advanced or Metastatic Cle...
PR NewswireUpdate: Halozyme Announces Presentation of Positive Clinical Data of its High-Volume Auto-Injector Demonstrating Successful Rapid Subcutaneous Drug Delivery at 13th Annual PODD: Partnership Opport...
PR NewswireHalozyme Announces Positive Clinical Data of its High-Volume Auto-Injector Demonstrating Successful Rapid Subcutaneous Drug Delivery
PR NewswireHalozyme to Present at Upcoming Investor Conferences
PR NewswireHalozyme Announces Approval of Roche's Tecentriq® Subcutaneous (SC) with ENHANZE® in Great Britain
PR NewswireHALOZYME REPORTS SECOND QUARTER 2023 FINANCIAL AND OPERATING RESULTS
PR NewswireHalozyme To Report Second Quarter 2023 Financial and Operating Results
PR NewswirePositive Topline Data Reported from argenx's ADHERE Study of VYVGART® Hytrulo with Halozyme's ENHANZE® Drug Delivery Technology in Patients with Chronic Inflammatory Demyelinating Polyneuropathy
PR NewswirePositive Results Announced from Phase 3 OCARINA II Trial Evaluating Roche's OCREVUS® (ocrelizumab) with Halozyme's ENHANZE® Drug Delivery Technology in Patients with Multiple Sclerosis
PR NewswireHalozyme Announces argenx Receives FDA Approval for VYVGART® Hytrulo With ENHANZE® for Subcutaneous Use in Generalized Myasthenia Gravis

Halozyme Therapeutics News

Halozyme Therapeutics News: auf dieser Seite finden Sie alle Halozyme Therapeutics News und Nachrichten zur Halozyme Therapeutics Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Halozyme Therapeutics News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Halozyme Therapeutics News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.